Prenatal diagnosis of methotrexate embryopathy
- PMID: 12738117
- DOI: 10.1016/s0029-7844(03)00120-0
Prenatal diagnosis of methotrexate embryopathy
Abstract
Background: Methotrexate is an antineoplastic agent used by obstetrician-gynecologists for termination of early pregnancy. The drug is not always successful and is associated with a known array of malformations.
Case: We present a case of a failed pregnancy termination with methotrexate, which resulted in fetal anomalies. Ultrasound revealed absent or markedly shortened long bones, abnormal positioning of the hands, micrognathia, echogenic bowel, and a two-vessel umbilical cord. The patient elected to undergo pregnancy termination, and the ultrasound findings were confirmed at autopsy.
Conclusion: Because of methotrexate's teratogenic potential, follow-up to confirm successful termination is necessary. Ultrasound evaluation of the fetus is indicated if pregnancy termination is unsuccessful.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
